Background: The optimal approach for adult patients hospitalized with severe and critical
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …

Background: Patients with primary cutaneous lymphoma receive immunosuppressive
therapy for long term disease control. Both cutaneous lymphoma and immunosuppressive …

OBJECTIVES: To evaluate safety and clinical outcomes of extracorporeal
immunomodulation treatment with a selective cytopheretic device (SCD) in COVID-19 ICU …

Objective: Patients with severe manifestations of COVID-19 might exhibit characteristics of a
sepsis-like syndrome that can progress to multiple organ failure and ultimately death …

Introduction: Extracorporeal hemoadsorption (HA) is a potential adjunctive therapy in severe
cases of COVID-19 associated pneumonia. In this retrospective study we report data from …

This study tried to investigate the impact of oXiris filter on both clinical and laboratory
parameters in critically‐ill COVID‐19 intensive care unit (ICU) patients receiving …

Introduction Although extracorporeal membrane oxygenation (ECMO) has been associated
with improved outcomes in COVID patients with respiratory failure, data regarding the need …

Background Recently, convalescent plasma (CP) transfusion was employed for severe or
critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients …

At least 20% of coronavirus disease 2019 (COVID-19) patients develop acute hypoxemic
respiratory failure requiring admission to intensive care unit (ICU) in 5–32% of the cases [1] …

Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …